ArticleBiomedicines2021

Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells-A View towards Second Line Renal Cell Carcinoma Treatment.

Eva Juengel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.